Solvent influences on metastable polymorph lifetimes: Real-time interconversions using energy dispersive X-ray diffractometry

被引:27
作者
Dematos, Luciana L.
Williams, Adrian C.
Booth, Steven W.
Petts, Catherine R.
Taylor, David J.
Blagden, Nicholas
机构
[1] Univ Reading, Sch Pharm, Reading RG6 6AD, Berks, England
[2] Univ Bradford, Sch Pharm, Bradford BD7 1DP, W Yorkshire, England
[3] Merck Sharp & Dohne Ltd, Hoddesdon EN11 9BU, Herts, England
[4] CLRC, Daresbury Lab, Warrington WA4 4AD, Cheshire, England
关键词
polymorph; hydrate; transformation; crystal growth; piracetam; in situ crystallization; solvent effects; energy dispersive X-ray diffraction; synchrotron;
D O I
10.1002/jps.20924
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Solvent influences on the crystallization of polymorph and hydrate forms of the nootropic drug piracetam (2-oxo-pyrrolidineacetamide) were investigated from water, methanol, 2-propanol, isobutanol, and nitromethane. Crystal growth profiles of piracetam polymorphs were constructed using time-resolved diffraction snapshots collected for each solvent system. Measurements were performed by in situ energy dispersive X-ray diffraction recorded in Station 16.4 at the synchrotron radiation source (SRS) at Daresbury Laboratory, CCLRC UK. Crystallizations from methanol, 2-propanol, isobutanol, and nitromethane progressed in a similar fashion with the initial formation of form I which then converted relatively quickly to form II with form III being generated upon further cooling. However, considerable differences were observed for the polymorphs lifetime and both the rate and temperature of conversion using the different solvents. The thermodynamically unstable form I was kinetically favored in isobutanol and nitromethane where traces of this polymorph were observed below 10 degrees C. In contrast, the transformation of form II and subsequent growth of form III were inhibited in 2-propanol and nitromethane solutions. Aqueous solutions produced hydrate forms of piracetam which are different from the reported monohydrate; this crystallization evolved through successive generation of transient structures which transformed upon exchange of intramolecular water between the liquid and crystalline phases. (c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 96:1069-1078, 2007.
引用
收藏
页码:1069 / 1078
页数:10
相关论文
共 36 条
[21]   Polymorph screening: Influence of solvents on the rate of solvent-mediated polymorphic transformation [J].
Gu, CH ;
Young, V ;
Grant, DJW .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (11) :1878-1890
[22]   Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs [J].
Gualtieri, F ;
Manetti, D ;
Romanelli, MN ;
Ghelardini, C .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (02) :125-138
[23]   ENERGY-DISPERSIVE DIFFRACTION WITH SYNCHROTRON RADIATION - OPTIMIZATION OF THE TECHNIQUE FOR DYNAMIC STUDIES OF TRANSFORMATIONS [J].
HAUSERMANN, D ;
BARNES, P .
PHASE TRANSITIONS, 1992, 39 (1-4) :99-115
[24]  
Knapman K., 2000, MODERN DRUG DISCOVER, V3, P53
[25]   Solvent selection for pharmaceuticals [J].
Kolár, P ;
Shen, JW ;
Tsuboi, A ;
Ishikawa, T .
FLUID PHASE EQUILIBRIA, 2002, 194 :771-782
[26]  
Kuhnert-Brandstatter M., 1994, SCI PHARM, V62, P307
[27]   Identifying the stable polymorph early in the drug discovery-development process [J].
Miller, JM ;
Collman, BM ;
Greene, LR ;
Grant, DJW ;
Blackburn, AC .
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2005, 10 (02) :291-297
[28]   Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes [J].
Morris, KR ;
Griesser, UJ ;
Eckhardt, CJ ;
Stowell, JG .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 48 (01) :91-114
[29]   On the advantages of the use of the three-element detector system for measuring EDXRD patterns to follow the crystallisation of open-framework structures [J].
Muncaster, G ;
Davies, AT ;
Sankar, G ;
Catlow, CRA ;
Thomas, JM ;
Colston, SL ;
Barnes, P ;
Walton, RI ;
O'Hare, D .
PHYSICAL CHEMISTRY CHEMICAL PHYSICS, 2000, 2 (15) :3523-3527
[30]  
OSTWALD Z, 1897, Z PHYS CHEM, V22, P289